Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and durable long-term treatment option.
Authors
- Nancy Cross
- Bengt Hoepken (ORCID: https://orcid.org/0000-0002-7487-8559)
- Kenneth B. Gordon (ORCID: https://orcid.org/0000-0002-9347-0292)
- Sarah Kavanagh (ORCID: https://orcid.org/0000-0003-0341-8261)
- Pablo Fernández‐Peñas (ORCID: https://orcid.org/0000-0003-4882-1564)
- L. Puig (ORCID: https://orcid.org/0000-0001-6083-0952)
- José M. López Pinto
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Delphine Deherder (ORCID: https://orcid.org/0000-0002-7336-1988)
- Jérémy Lambert (ORCID: https://orcid.org/0000-0002-7164-1492)
- Richard G. Langley (ORCID: https://orcid.org/0000-0003-4730-2164)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Akimichi Morita (ORCID: https://orcid.org/0000-0001-8372-3754)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Bruce E Strober (ORCID: https://orcid.org/0000-0002-8394-2057)
Institutions
- Universitat Autònoma de Barcelona (ES)
- The University of Sydney (AU)
- Dalhousie University (CA)
- Medical College of Wisconsin (US)
- North Carolina Institute of Medicine (US)
- Manchester Academic Health Science Centre (GB)
- Hospital de Sant Pau (ES)
- Westmead Hospital (AU)
- Yale University (US)
- Nagoya City University (JP)
- UCB Pharma (France) (FR)
- UCB Pharma (Germany) (DE)
- UCB Pharma (Belgium) (BE)
- Dominican College of Blauvelt (US)
- University of Lübeck (DE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1016/j.jaad.2025.04.038
- Citations
- 9
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 31.45
Funders
- Sanofi
- Union Chimique Belge
- Sanofi Genzyme